(Q30351736)

20 June 2017

1 reference

title

Oseltamivir in the management of influenza. (English)

1 reference

20 June 2017

1 reference

1

John Oxford

1 reference

20 June 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

Expert Opinion on Pharmacotherapy

20 June 2017

published in

1 reference

20 June 2017

volume

6

1 reference

20 June 2017

issue

14

1 reference

20 June 2017

page(s)

2493-2500

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

20 June 2017

1 reference

Stimulation of tumor necrosis factor secretion by purified influenza virus neuraminidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

H5N1 influenza and the implications for Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Zanamivir in the treatment of influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

RNA virus mutations and fitness for survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Structure of the catalytic and antigenic sites in influenza virus neuraminidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Avian influenza--a challenge to global health care structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Controlling avian flu at the source

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

The structure and function of the hemagglutinin membrane glycoprotein of influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

The neuraminidase of influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Oseltamivir distributes to influenza virus replication sites in the middle ear and sinuses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Oseltamivir: a review of its use in influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Early administration of oral oseltamivir increases the benefits of influenza treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Quantification of the influenza virus load by real-time polymerase chain reaction in nasopharyngeal swabs of patients treated with oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Oral oseltamivir treatment of influenza in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Detection and control of influenza outbreaks in well-vaccinated nursing home populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Safety and pharmacology of oseltamivir in clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Treatment of influenza with neuraminidase inhibitors: virological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Resistant influenza A viruses in children treated with oseltamivir: descriptive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Position statement: global neuraminidase inhibitor susceptibility network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

Global task force for influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2493

10.1517/14656566.6.14.2493

21 January 2018

Identifiers

DOI

1 reference

20 June 2017

1 reference